Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling.
Steelman LS, Chappell WH, Akula SM, Abrams SL, Cocco L, Manzoli L, Ratti S, Martelli AM, Montalto G, Cervello M, Libra M, Candido S, McCubrey JA. Steelman LS, et al. Among authors: chappell wh. Adv Biol Regul. 2020 Dec;78:100758. doi: 10.1016/j.jbior.2020.100758. Epub 2020 Sep 28. Adv Biol Regul. 2020. PMID: 33022466 Review.
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.
McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM. McCubrey JA, et al. Among authors: chappell wh. Adv Enzyme Regul. 2007;47:64-103. doi: 10.1016/j.advenzreg.2006.12.013. Epub 2007 Mar 26. Adv Enzyme Regul. 2007. PMID: 17382374 Free PMC article. No abstract available.
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.
McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS. McCubrey JA, et al. Among authors: chappell wh. Adv Enzyme Regul. 2008;48:113-35. doi: 10.1016/j.advenzreg.2008.02.006. Epub 2008 Feb 21. Adv Enzyme Regul. 2008. PMID: 18423407 Free PMC article.
Akt as a therapeutic target in cancer.
Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. Steelman LS, et al. Among authors: chappell wh. Expert Opin Ther Targets. 2008 Sep;12(9):1139-65. doi: 10.1517/14728222.12.9.1139. Expert Opin Ther Targets. 2008. PMID: 18694380 Review.
Targeting the cancer initiating cell: the Achilles' heel of cancer.
McCubrey JA, Chappell WH, Abrams SL, Franklin RA, Long JM, Sattler JA, Kempf CR, Laidler P, Steelman LS. McCubrey JA, et al. Among authors: chappell wh. Adv Enzyme Regul. 2011;51(1):152-62. doi: 10.1016/j.advenzreg.2010.09.002. Epub 2010 Oct 28. Adv Enzyme Regul. 2011. PMID: 21035484
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM. McCubrey JA, et al. Among authors: chappell wh. J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. J Cell Physiol. 2011. PMID: 21302297 Review.
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.
Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Sokolosky ML, et al. Among authors: chappell wh. Oncotarget. 2011 Jul;2(7):538-50. doi: 10.18632/oncotarget.302. Oncotarget. 2011. PMID: 21730367 Free PMC article.
43 results